The Next Generation of Alzheimer’s Treatment: Harnessing Microglia with TREM2 Agonism
Time: 1:30 pm
day: Clinical & Commercial Track Day 2 PM
Details:
- Harnessing neuroprotective microglial states for the next generation of AD treatment
- Potent small molecule TREM2 agonists that act as molecular glues to stabilize a multimeric signalling complex
- Genetic and biomarker strategies to aid early development and how a small molecule TREM2 agonist may address unmet needs in AD
